CD19 Antibody (HD237): sc-18884
- CD19 Antibody (HD237) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 200 µg/ml
- recommended for detection of CD19 of human origin by IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also provided azide-free for blocking, sc-18884 L, 200 µg/0.1 ml
- See CD19 (B-1): sc-390244 for CD19 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD19 Antibody (HD237). This work is in progress.
QUICK LINKS
SEE ALSO...
CD19 Antibody (HD237) is a mouse monoclonal IgG2b light chain antibody that detects CD19 in human samples through applications such as immunofluorescence (IF) and flow cytometry (FCM). CD19 is a crucial transmembrane glycoprotein that plays a significant role in B-cell development and activation. CD19 is selectively expressed on the surface of B-lymphocytes, where CD19 is integral to the activation of intracellular signaling pathways, including the Ras and phosphatidylinositol 3-kinase pathways. CD19′s importance lies in CD19′s ability to facilitate the cross-linking of immunoglobulin chains, which leads to the recruitment of Src family protein tyrosine kinases, essential for B-cell signaling. CD19′s expression is maintained throughout the various stages of B-cell maturation, culminating in the differentiation of B-cells into plasma cells. Additionally, CD19 forms functional complexes with other B-lymphocyte surface proteins, such as integrin β1, CD21, and CD81, which are vital for regulating B-cell development and ensuring a robust immune response. Anti-CD19 antibody (HD237) is an invaluable tool for researchers studying B-cell biology and related immunological processes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD19 Antibody (HD237) References:
- CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. | Ortíz-Maldonado, V., et al. 2021. Mol Ther. 29: 636-644. PMID: 33010231
- Beyond CD19 CAR-T cells in lymphoma. | Leung, WK., et al. 2022. Curr Opin Immunol. 74: 46-52. PMID: 34800921
- CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. | Gambella, M., et al. 2022. Front Immunol. 13: 837457. PMID: 35280988
- B cell receptor-induced IL-10 production from neonatal mouse CD19+CD43- cells depends on STAT5-mediated IL-6 secretion. | Sakai, J., et al. 2023. Elife. 12: PMID: 36735294
- Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy. | Duell, J., et al. 2024. Blood. 143: 685-696. PMID: 37976456
- IL-10+CD19+ regulatory B cells induce CD4+Foxp3+regulatory T cells in serum of cervical cancer patients. | Yang, C., et al. 2024. Autoimmunity. 57: 2290909. PMID: 38084896
- Solving the mystery of the FMC63-CD19 affinity. | Seigner, J., et al. 2023. Sci Rep. 13: 23024. PMID: 38155191
- Decreased CD19+CD24hiCD38hi Regulatory B Cells in Alopecia Areata. | Lee, JY., et al. 2024. J Invest Dermatol. 144: 2080-2083.e7. PMID: 38387525
- Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. | Zhu, H., et al. 2024. EBioMedicine. 103: 105098. PMID: 38608514
- Aggressive Lymphoma after CD19 CAR T-Cell Therapy. | Kobbe, G., et al. 2024. N Engl J Med. 391: 1217-1226. PMID: 39589371
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD19 Antibody (HD237) | sc-18884 | 200 µg/ml | $322.00 | |||
CD19 Antibody (HD237) FITC | sc-18884 FITC | 200 µg/ml | $336.00 | |||
CD19 Antibody (HD237) L | sc-18884 L | 200 µg/0.1 ml | $322.00 | |||
CD19 Antibody (HD237) PE | sc-18884 PE | 200 µg/ml | $349.00 |